Rapid Dose Issues Q1 2020 Financial Results
Rapid Dose Therapeutics (CSE:DOSE) released its financial results for Q1 of the fiscal 2020 year. As quoted in the press release: “This quarter represents a very exciting milestone for RDT as we commence the recognition of revenues from initial sales of our Energy, Vitamin B12, and Sleep QuickStrip™ nutraceutical products,” said Mark Upsdell, CEO of RDT. “Revenues from … Continued
Rapid Dose Therapeutics (CSE:DOSE) released its financial results for Q1 of the fiscal 2020 year.
As quoted in the press release:
“This quarter represents a very exciting milestone for RDT as we commence the recognition of revenues from initial sales of our Energy, Vitamin B12, and Sleep QuickStrip™ nutraceutical products,” said Mark Upsdell, CEO of RDT. “Revenues from the delivery of QuickStrip™ production equipment and recurring revenues for cannabis products will begin in Q2.”
First Quarter Highlights
-
Commencement of revenue recognition from the sale of QuickStrip™ nutraceutical products
-
Appointment of Mr. Ian Fodie as Chief Financial Officer
-
Signing of Distribution Agreement with TFB & Associates Ltd. for QuickStrip™ nutraceutical products in Canada
-
Signing of Memorandum of Understanding with Thrive Cannabis providing Thrive the right to sell RDT’s proprietary QuickStripTM technology using cannabis distillate in Canada
Click here to read the full press release.
